Loading
The t(11;14) translocation parks the cyclin D1 gene next to the antibody gene's accelerator, flooding the cell with a protein that pushes it through division; a brown nuclear stain for cyclin D1 (plus SOX11) is how mantle cell lymphoma is confirmed, and in myeloma the same translocation marks the patients who respond to venetoclax.
What is measured: the IGH::CCND1 translocation and the proteins that go with it. How: cyclin D1 immunohistochemistry (nuclear staining in over 95 percent of mantle cell lymphomas; the rare negatives carry CCND2 or CCND3 rearrangements and are caught by SOX11 positivity), FISH for CCND1::IGH on tissue, blood or marrow, karyotype, and SOX11 immunohistochemistry, which is positive in classic nodal mantle cell lymphoma and negative in the indolent leukaemic non-nodal form (IGHV-mutated, often CD5-negative). In myeloma, FISH panels find t(11;14) in 15 to 20 percent, a standard-risk lesion whose cells depend on BCL2, and more often in AL amyloidosis and plasma cell leukaemia. What a result changes: it separates mantle cell lymphoma from CLL and small lymphocytic lymphoma (cyclin D1-negative, LEF1-positive) and follicular lymphoma; SOX11-negative leukaemic non-nodal disease can often be observed; in myeloma, t(11;14) selects patients for venetoclax-based regimens (a BELLINI subgroup, CANOVA, and NCCN listing off label) and predicts BCL2-inhibitor response in AL amyloidosis. Where it matters: mantle cell lymphoma, plasma cell leukaemia and relapsed myeloma.
In plain words · CCND1 (G1/S-specific cyclin-D1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker, a fusion partner and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Skin cancer, Multiple myeloma and 5 more.
Showing the target this term concerns: CCND1.
Shares Cytogenetics and karyotype, FISH / ISH (in situ hybridisation), BCL-2, Venetoclax.
Shares Ibrutinib, Venetoclax, Mantle cell lymphoma, Non-Hodgkin lymphoma (all types).
Shares MIPI (Mantle Cell Lymphoma International Prognostic Index), TP53 mutation and del(17p), Cytogenetics and karyotype, Plasma cell leukaemia.
Shares Ibrutinib, BCL-2, Venetoclax, Mantle cell lymphoma.
Shares Cytogenetics and karyotype, FISH / ISH (in situ hybridisation), BCL-2, Non-Hodgkin lymphoma (all types).
Shares BCL-2, Venetoclax, Mantle cell lymphoma, Non-Hodgkin lymphoma (all types).
Shares The cell-cycle engine (cyclins & CDKs), CDK4/6, TP53.
Shares CCND1, Ibrutinib, Mantle cell lymphoma, Non-Hodgkin lymphoma (all types).